Oragenics Inc - Asset Resilience Ratio
Oragenics Inc (OGEN) has an Asset Resilience Ratio of 39.73% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OGEN working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Oragenics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Oragenics Inc.
Liquid Assets Composition Over Time
This chart breaks down Oragenics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read OGEN liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.00 Million | 39.73% |
| Total Liquid Assets | $4.00 Million | 39.73% |
Asset Resilience Insights
- Very High Liquidity: Oragenics Inc maintains exceptional liquid asset reserves at 39.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oragenics Inc Industry Peers by Asset Resilience Ratio
Compare Oragenics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Oragenics Inc (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Oragenics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.73% | $4.00 Million | $10.07 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $1.47 Million | -- |
| 2022-12-31 | 0.12% | $17.94K | $14.76 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $7.21 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $4.31 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $5.78 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $11.13 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $16.83 Million | -- |
| 2012-12-31 | 0.59% | $62.00K | $10.49 Million | -20.33pp |
| 2011-12-31 | 20.92% | $265.00K | $1.27 Million | -6.64pp |
| 2010-12-31 | 27.55% | $476.00K | $1.73 Million | -48.94pp |
| 2009-12-31 | 76.49% | $2.45 Million | $3.20 Million | -- |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation w… Read more